Compare Amgen, Inc. (AMGN) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Marvell Technology Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Marvell Technology Inc trades at $217.81 (market cap $190.56B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | MRVL | |
|---|---|---|
Market Cap | $224.14B | $190.56B |
Sector | Health | Technology |
52-Week High | $417.20 | $316.43 |
52-Week Low | $271.18 | $62.31 |
Enterprise Value | $267.45B | $191.99B |
Dividend Yield | 2.43% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Marvell Technology (MRVL) trades at $221.86, up 6.38% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and revenue growth to $5.77 billion in 2025. Analyst consensus remains strongly bullish with 82% buy ratings and a $275.68 price target, representing 24% upside potential. Recent news highlights Marvell's positioning in AI infrastructure and optical networking leadership.
Marvell presents significant growth potential driven by AI data center expansion and custom chip programs with Microsoft and NVIDIA. However, investors face risks from premium valuations (P/E 72.96), supply chain constraints, and competitive pressure from Broadcom and AMD. The stock's recent volatility and high beta characteristics require careful risk management despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
